Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

    Contact

    Investor Relations                          Media Relations

    John Calhoun, MD, MBA                       Susan W. Specht, MBA

    Director, Corporate Communications &        Associate Director, Corporate

     Investor Relations                          Communications

    (206) 442-6744                              (206) 442-6592

CONTACT: investors, John Calhoun, MD, MBA, Director, CorporateCommunications & Investor Relations, +1-206-442-6744, or media, Susan W.Specht, MBA, Associate Director, Corporate Communications, +1-206-442-6592both of ZymoGenetics, Inc.

Web site: http://www.zymogenetics.com//

Ticker Symbol: (NASDAQ-NMS:ZGEN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... , Dec. 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... pharmacy, is proud to announce Jennifer Hagerman , ... Diplomat, will take office as the president of the ... induction ceremony will take place Feb. 28, 2015, at ... held at the Renaissance Center in Detroit, ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical ... company engaged primarily in the development of brachytherapy ... applications, today announced that it has filed a ... and Drug Administration ("FDA") for marketing clearance for ... 513(f)(2) of the U.S. Food, Drug and Cosmetic ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Sept. 28 Delcath Systems, Inc. (Nasdaq: DCTH ... Blair Emerging Growth Stock Conference on Tuesday, October 5, 2010 ... McDonald, Chief Financial Officer, will provide an overview of the ... at this conference is by invitation only. Delcath will offer ...
... be giving their children more medicine than they ... week at Research Forum during Scientific Assembly, the ... Physicians.  Two studies are raising concern about over-the-counter ... Inaccurate" and "Do Parents in the Emergency Department ...
Cached Medicine Technology:Delcath to Present at the William Blair Emerging Growth Stock Conference 2Warnings Re: Over-the-Counter Medication for Children: Less is More 2
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... over an existing treadmill and allows employees to walk and work simultaneously, ... ... 2008 -- Wouldn,t it be wonderful if there was a product that ... shed excess weight and make them more productive? , , , , ...
... risk, study finds , , TUESDAY, Oct. 21 (HealthDay News) -- ... the first time in a decade, particularly among middle-aged white ... we haven,t had as much focus on in terms of ... males, and there has been a lot of attention to ...
... Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading fully ... People,s Republic of China ("PRC"), announced today ... Co. Ltd.,("Harbin First Bio-Engineering"), received $800,000 in ...
... PLYMOUTH MEETING, Pa., Oct. 21 Genaera,Corporation (Nasdaq: ... NASDAQ that the bid price of the Company,s common ... under NASDAQ,Marketplace Rule 4310(c)(4) for the last 30 consecutive ... as of October 16, 2008 it has,suspended for a ...
... BASKING RIDGE, N.J., Oct. 21 Hooper ... Heritage Labs division was awarded a,contract to manufacture ... Westat, an employee-owned corporation providing research services,to agencies ... foundations, and,state and local governments. This component of ...
... are Effective in,Treating Triple-Negative Beast Cancer, According to ... Oct. 21 Decision Resources, one of the,world,s ... issues, finds that significant market penetration will drive,Genentech/Roche/Chugai,s ... total,sales in the breast cancer drug market in ...
Cached Medicine News:Health News:Help Employees Boost Memory, Lose Weight, Get Healthier & Increase Productivity 2Health News:Suicide Rates Rise Among Baby Boomers 2Health News:Suicide Rates Rise Among Baby Boomers 3Health News:China Sky One Medical, Inc. Receives Tax Refund 2Health News:China Sky One Medical, Inc. Receives Tax Refund 3Health News:Genaera Receives Non-Compliance Notice From NASDAQ 2Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 2Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 3Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 4Health News:Genentech/Roche/Chugai's Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017 2
For the quantitative in vitro determination of Carbamazepine in human serum...
For the quantitative in vitro determination of Phenobarbital in human serum....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with particulate (silica) activator....
Medicine Products: